Recent data indicate that in situ injection of the thermogel Gel@B-B containing the Glut1 inhibitor BAY-876 and a blocker of PD-1/PD-L1 BMS-1 significantly delays tumor growth, prolongs survival time and improves ICB treatment outcomes in an in situ mouse model of GBM by dual modulation of metabolism and immunity in glioblastoma (GBM) (Li et al., 2024). Here, PDCD1 is linked to glioblastoma.